ABOUT THE PROJECT
Immune checkpoint inhibitor (ICI) therapies have transformed clinical cancer care, particularly in tumours with mismatch repair deficiency. However, there is wide inter-individual variability in response, limiting its application in clinical practice. Preliminary results suggest that quantification of the level of microsatellite instability (MSI) may account for response variability in MMR-deficient tumours.
The main aim of the project is to assess the usefulness of MSI intensity assessment as a pan-cancer biomarker to predict and monitor ICI treatment response in patients with MSI tumours.
If you have any doubts or concerns about this research team, contact us by filling this form